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Antiphospholipid antibodies enhance rat
neonatal cardiomyocyte apoptosis in an in vitro
hypoxia/reoxygenation injury model via p38 MAPK
Lauren T Bourke1,2, Thomas McDonnell1, James McCormick3, Charis Pericleous1, Vera M Ripoll1, Ian Giles1, Anisur Rahman1,
Anastasis Stephanou4 and Yiannis Ioannou*,1,2
A significant amount of myocardial damage during a myocardial infarction (MI) occurs during the reperfusion stage, termed
ischaemia/reperfusion (I/R) injury, and accounts for up to 50% of total infarcted tissue post-MI. During the reperfusion phase, a
complex interplay of multiple pathways and mechanisms is activated, which ultimately leads to cell death, primarily through
apoptosis. There is some evidence from a lupus mouse model that lupus IgG, specifically the antiphospholipid (aPL) antibody
subset, is pathogenic in mesenteric I/R injury. Furthermore, it has previously been shown that the immunodominant epitope for the
majority of circulating pathogenic aPLs resides in the N-terminal domain I (DI) of beta-2 glycoprotein I (β2GPI). This study describes
the enhanced pathogenic effect of purified IgG derived from patients with lupus and/or the antiphospholipid syndrome in a
cardiomyocyte H/R in vitromodel. Furthermore, we have demonstrated a pathogenic role for aPL containing samples, mediated via
aPL–β2GPI interactions, resulting in activation of the pro-apoptotic p38 MAPK pathway. This was shown to be inhibited using a
recombinant human peptide of domain I of β2GPI in the fluid phase, suggesting that the pathogenic anti-β2GPI antibodies in this
in vitro model target this domain.
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The antiphospholipid syndrome (APS) is characterised by the
clinical syndrome of arterial and venous thrombosis and/or
recurrent pregnancy morbidity in association with the pre-
sence of antiphospholipid (aPL) antibodies.1 Βeta-2 glycopro-
tein I (β2GPI) consists of five homologous peptide subunits,
which are termed domains I to V2,3 with domain V being
responsible for binding anionic phospholipid.4 A subpopula-
tion of aPL derived from patientswith APS binds phospholipids
via domain I of the protein co-factor β2GPI to promote
thrombosis,5,6 and these anti-DI antibodies have been proven
to be pathogenic in an animal model of venous thrombosis.7,8
Myocardial infarction (MI) is an important cause of morbidity
and mortality in systemic lupus erythematosus (SLE) and
many patients with SLE also have co-existing APS. It is widely
accepted that accelerated atherosclerosis is a key contributor
to cardiovascular-related morbidity and mortality in lupus;
however, the role of I/R injury is yet to be explored. APS is
associated with a greater risk of atherosclerosis compared
with matched controls9 and accounts for one in nine MIs.10
There is some evidence within a lupus mouse mesenteric I/R
injury model that lupus IgG are pathogenic.11 Additionally
aPL, which are found in 30–40% of lupus patients,12 as well
as those with only APS (primary APS) has been shown to
specifically restore mesenteric I/R injury in a complement
deficient mouse model.13 Therefore, if relevant to the
myocardium, one might expect that cardiac infarct size post-
MI would be larger in patients with SLE and/or APS. However,
to our knowledge no large-scale study has been undertaken to
compare cardiac infarct sizes between patients with SLE±
APS and age- and gender-matched controls. Given that
patients with SLE have greater cardiovascular risks and
increased mortality due to cardiovascular events,14 it is
relevant to investigate if, at the experimental level, IgG from
SLE and/or APS enhance cardiac I/R injury.
During the reperfusion phase of I/R injury, a complex
interplay of multiple pathways and mechanisms is activated,
which ultimately culminate in cell death primarily through
apoptosis. In vivo rat studies have shown that the number of
TUNEL (terminal deoxynucleotidyl transferase-mediated
dUTP nick-end labelling)-positive cardiomyocytes in I/R injury
can be reduced by treatment with a caspase inhibitor,15
resulting in a reduced infarct size indicating that apoptosis
plays an important role in I/R-induced damage. The mitogen-
activated protein kinase (MAPK) family, which consists of a
series of serine–threonine kinases, is known to play a role in
cell proliferation, differentiation and survival, but have also
been shown to be heavily implicated in I/R injury in both a pro-
and anti-apoptotic fashion. Specifically, in vivo animal studies
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have shown that inhibition of p38 MAPK via SB203580 results
in a reduction in myocardial damage16 and improved cardiac
function.17 Inhibition of p38 MAPK also leads to a reduction in
inflammatory cytokines such as tumour necrosis factor alpha
(TNF-α), interleukin-1 (IL-1) and interleukin-8 (IL-8), therefore
reducing the pro-inflammatory response which is known to
contribute to cardiac I/R injury.18
In the presence of serum co-factors, such as β2GPI,
pathogenic anti-PL binds negatively charged PL such as
cardiolipin (CL).19 This has been shown to result in an aPL-
mediated activation of p38 MAPK and NF-κB pathways in
cultured human endothelial cells20 and monocytes.21–23 One
may hypothesise that if β2GPI-dependent aPL were to also
activate p38 MAPK in cardiomyocytes, then this would
enhance apoptosis in cardiac I/R injury.
Here, we describe a pathogenic role for aPL antibodies in an
in vitro model of cardiomyocyte hypoxia/reoxygenation (H/R)
injury. This injury is shown to be induced via the pro-apoptotic
p38 MAPK. Furthermore, in the absence of β2GPI or the
presence of a recombinant human DI decoy peptide patho-
genicity was abrogated, suggesting this effect is mediated
through antibodies targeting DI of β2GPI.
Results
Clinical and laboratory characteristics of individuals. A
total of 11 patients with APS, 9 SLE/aPL negative (APS
negative) and 15 healthy controls (HCs) subjects were
studied (Table 1). Of the 35 subjects, 28 were female. Of
11 patients with APS, 5 had SLE (clinical and serological
details are shown in Table 1) and 6 primary APS.
IgG purified from patients with SLE enhances apoptosis
in neonatal rat cardiomyocytes within an in vitro H/R
injury model. An in vitro simulated model of cardiac H/R
injury was used, whereby neonatal rat cardiomyocytes were
isolated and pre-treated with 500 μg/ml IgG purified from
patients with SLE and HC, and then exposed to H/R injury.
Pre-incubation with HC IgG resulted in an increase of 7.3%
(±S.D. 3.9, n= 5) in TUNEL-positive cells compared with
untreated cells exposed to H/R injury (Figure 1). However,
when cells were pre-incubated with IgG purified from patients
with SLE, TUNEL positivity was significantly enhanced
further to 54.2% (±S.D. 8.1, n=6, P=0.0043).
To assess if this pro-apoptotic role for SLE autoantibodies
in this in vitro H/R was dependent on the presence of APS-
related autoantibodies, further experiments were performed
using another marker of apoptosis, cleaved caspase-3 and an
expanded set of patient IgG samples allowing groups to be
compared between those that are SLE/APS positive versus
SLE/APS negative and APS alone. Figure 2 shows effects on
cleaved caspase-3 upon incubation with IgG from the different
subject groups. SLE-derived IgG had a pro-apoptotic effect in
this model but the presence of APS-derived IgG had a
significantly greater pro-apoptotic effect over and above that
seen in SLE/APS-negative IgG. Compared with untreated
cells, HC IgG treatment did not alter cleaved caspase-3 levels
whereas these levels were significantly increased by 68.15%
(±S.D. 13.5, n= 5, Po0.0005) in the presence of SLE/APS
IgG and by 67.94% (±S.D. 12.41, n=6, Po0.0005) in the
presence of primary APS IgG but by only 40.66% (±S.D. 8.7,
n= 5, Po0.0005) in the presence of SLE/APS-negative IgG.
Thus, since the two APS groups gave very similar results we
chose to combine them in subsequent experiments reported in
this paper, which all compare three groups: APS, SLE/APS
negative and HC.
The pathogenic effect of APS IgG is dependent upon
enhanced phosphorylation of the pro-apoptotic MAPK
p38 in neonatal rat cardiomyocytes within an in vitro H/R
injury model. Enhancement of MAPK p38 phosphorylation
was observed in the presence of APS IgG but not SLE/APS-
negative IgG when compared with cells treated with HC IgG
during H/R injury (Figure 3a). The mean ratio of phosphory-
lated to total p38 MAPK was 0.52 (±S.D. 0.37) in cells
treated with APS IgG versus 0.12 (±S.D. 0.12) in cells
treated with SLE/APS-negative IgG (P=0.0174). However,
APS IgG did not significantly affect levels of Akt and ERK 1/2
phosphorylation (Figures 3b and c). It should be noted that
the p44 isoform of ERK 1/2 had reduced phosphorylation in
the presence of APS IgG when compared with SLE/APS-
negative IgG, although this was not significantly different.
Co-incubation with a p38 MAPK-specific inhibitor
(SB23580) reduced the effect of APS IgG on levels of cleaved
caspase-3 (Figure 4). Thus, cleaved caspase-3 levels relative
to GAPDHwas 0.81 (±S.D. 0.17) in the presence of APS IgG,
but 0.40 (±S.D. 0.14) in the presence of APS IgG plus
SB23580 (P= 0.029). In fact, presence of this inhibitor
reduced cleaved caspase-3 almost to the levels seen with
Table 1 Clinical characteristics and binding properties of patient cohort
Primary APS (n= 6) SLE/aPL+ve (n=5) SLE/aPL –ve
(n= 9)
Healthy controls
(n= 15)
Age (mean±SEM) 55 (±4.5) 45.2 (±5.1) 42.8 (±6.3) 35.2 (±4.7)
Sex 3 F/3 M 5 F 8 F 8 F/2 M
Serum aCL (mean GPLU±SEM) 50.0 (±20.65) 43.26 (±15.83) 3.62 (±0.34) 4.12 (±0.58)
Serum anti-β2GPI (mean SU±SEM) 91.6 (±19.7) 49.62 (±16.1) 3.58 (±0.3) 5.4 (±0.7)
Serum anti-DI (mean as a % binding to an in-
house standard)
35.56 (±38.96) 11.85 (±3.98) 4.20 (±2.57) 3.56 (±1.78)
Patients with APS (n= 11) are separated into clinical groups (primary APS and SLE/APS positive). The mean age (±S.D.) of each patient subgroup and for the HC
group is also shown. Purified polyclonal IgG was tested in aCL, anti-β2GPI and anti-DI (of β2GPI) direct binding assays and mean values (from duplicate
experiments±S.D.) are shown here. For aCL, mean activity is shown in GPLU, anti-β2GPI is shown in GDU (IgG arbitrary units) and anti-DI as the percentage activity
of an in-house standard
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SLE/APS-negative IgG −0.29 (±S.D. 0.12) but not to levels
seen with HC IgG − 0.12 (±S.D. 0.1). No significant effect on
cleaved caspase-3 level was observed with the p38 inhibitor in
cells that were untreated, or treated with HC IgG or SLE/APS-
negative IgG.
Removal of β2GPI from serum abrogates the pathogenic
effect of APS-positive IgG in neonatal rat cardiomyocytes
within an in vitro H/R injury model. The depletion of β2GPI
from human serum led to loss of the pathogenic effect of APS
IgG on cleaved caspase-3 levels when exposed to H/R injury.
When cells cultured in β2GPI-deficient serum were spiked
with human β2GPI, the pathogenic effect of APS-positive IgG
was restored (Figure 5a).
A recombinant human DI decoy peptide blocks the
pathogenic effect of APS-positive IgG in neonatal rat
cardiomyocytes within an in vitro H/R injury model.
Purified IgG was pre-incubated with recombinant DI for 2 h
prior to incubation with cells. In the presence of the DI peptide
the effect of APS IgG on cleaved caspase-3 was inhibited
(Figure 5b). In cells treated with APS IgG and exposed to H/R
injury, the addition of DI peptide led to a 48.81% (±S.D. 34.07)
inhibition in cleaved caspase-3 level. Addition of DI caused
much smaller reductions in levels of cleaved caspase-3
in cells treated with HC IgG (reduction 3.14% (±S.D.
7.9)−P=0.0045 compared with APS IgG) or SLE/APS-
negative IgG (reduction 6.2% (±S.D. 10.84)−P=0.0145
compared with APS IgG).
In addition, the ability of the recombinant DI to inhibit binding
of IgG from the APS patient cohort to solid-phase β2GPI was
measured by ELISA. Importantly, serum from all nine patients
had demonstrated high activity in our in-house solid-phase
β2GPI ELISA assay. The ability of recombinant DI at
concentrations ranging from 0 to 80 μg/ml to inhibit binding
of all nine sera to solid-phase β2GPI in this assay was then
tested. Figure 5c shows that six serum samples were inhibited
by the presence of the DI peptide to different degrees.
Figure 5d compares the reduction in cleaved caspase-3
caused by DI in cultured cardiomyocytes exposed to APS IgG
samples from individual patients with the percentage by which
binding to β2GPI of the same APS IgG samples is inhibited by
DI at the same concentration (40 μg/ml). There was a positive
correlation between these two separate measures of DI
inhibition of these samples (r= 0.6775, P=0.0459).
Discussion
A novel pathogenic role for aPL autoantibodies has been
identified by demonstrating a pro-apoptotic effect within an
in vitro model of cardiomyocyte H/R injury. Furthermore, the
mechanism through which this pathogenic effect may be
mediated has been dissected using a range of time points to
fully understand this complex interplay of signalling pathways.
Fleming et al.13 have previously shown that in amesenteric I/R
injury model that anti-β2GPI autoantibodies restore local and
remote tissue damage in a Complement Receptor 2/Comple-
ment Receptor 1-Deficient mouse model that is typically
Figure 1 IgG from patients with SLE enhances the number of TUNEL-positive cells in neonatal rat cardiomyocytes exposed to H/R injury. Neonatal rat cardiomyocytes were
pre-treated with 500 μg/ml IgG from either healthy or SLE patients and the following day cells were exposed to H/R injury (4 h hypoxia+16 h reoxygenation). Cells were fixed in 4%
PFA and the percentage of TUNEL-positive cells was assessed. Graph shows mean ±S.E.M. of quantitative analysis from six SLE patients and five healthy controls. Statistical
analysis was determined by Mann–Whitney U-test (**P= 0.0043)
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protected from I/R injury. Owing to previous studies showing
that I/R injury mechanisms are similar in a variety of tissue
types13 and patients with APS having a greater risk of
myocardial infarction,24 one may hypothesise that aPL
antibodies play a pathogenic role also in the setting of the
myocardium. This study has found that IgG purified from
patients with SLE and/or APS enhanced apoptosis, as
measured by an increase in TUNEL positivity (Figure 1).
Levels of cleaved caspase-3 were also assessed in a larger
cohort of patients and this pathogenic effect was confirmed
(Figure 2). Moreover, enhanced cleaved caspase-3 was most
pronounced in those patients who were APS positive (SLE/
aPL positive and primary APS), suggesting an aPL-dependent
mechanism of pathogenicity distinct from patients with SLE.
Experiments were performed to identify potential mechan-
isms through which IgG from patients with APS caused
pathogenicity in this H/R injury model. We found that APS IgG
enhanced p38 MAPK phosphorylation significantly more than
SLE/APS negative or HC IgG and that a p38 MAPK inhibitor
(SB203580) reduced the increase in cleaved caspase-3
caused by APS IgG (Figure 4) This suggests that the
enhanced pro-apoptotic effect of APS IgG is due to increased
phosphorylation of the kinase p38 MAPK. The use of p38
MAPK inhibitors in the treatment of cardiac I/R injury is
currently being explored in a number of trials.25 In untreated
cells, while p38 MAPK is enhanced by H/R injury, levels
observed are low compared with APS IgG-treated cells. It
could therefore be suggested that the p38 MAPK contribution
to H/R injury in the presence of a p38 MAPK stimulus such as
APS IgG is greater and therefore an inhibitor would be more
effective in reducing the pathogenic effects mediated by p38
MAPK in patients with APS.
It is acknowledged that in APS the dominant population of
pathogenic autoantibodies target the circulating autoantigen
β2GPI.
26–29 To demonstrate if this APS IgG-mediated patho-
genicity of cardiomyocyte H/R injury was mediated through
β2GPI autoantibodies, cells were cultured in media containing
β2GPI-deficient human serum in the presence of IgG from the
different groups studied. It was observed that in the absence of
this serum co-factor, there was a reduction in cleaved
caspase-3 in the presence of APS IgG (Figure 5a), but when
human β2GPI was added back into the system to a final
concentration typically observed in humans, levels of cleaved
caspase-3 were enhanced back to levels similar to that seen
previously. This result did not reach statistical significance,
with a noted limitation of this experiment being that pooled IgG
was used, therefore potentially dampening the response
observed by specific patient samples.
Although SLE/APS-negative IgG samples did have an effect
on cleaved caspase-3 it was smaller than that of APS IgG.
Also SLE/APS-negative IgG had no effect on MAPK p38
phosphorylation. This suggests an alternative mechanism of
pathogenicity for this polyclonal population of IgG. Many
different autoantibody specificities have been identified in
SLE. Anti-Ro antibodies can affect the fetal heart
causing neonatal lupus play and could also have effects in
adults;30 however, clinical data confirm that the majority of our
patients are anti-Ro negative. It is possible that a yet to be
identified population of antibodies may be pathogenic in this
model of cardiomyocyte H/R injury. Further studies are now
required to try and identify both the autoantibody populations
and the epitopes to which they bind to cause a pathogenic
effect.
Studies using domain deletion mutants of β2GPI, in which
one or more domains are missing, have shown that the
immunodominant epitope which binds the pathogenic anti-
β2GPI APS autoantibodies is located in DI
5,6 and recombinant
DI can bind these APS autoantibodies in both the solid and
fluid phase.31,32 Pre-incubating APS-positive IgG from indivi-
dual patients with recombinant human DI, prior to treatment of
cells, reduced cleaved caspase-3 in H/R injury (Figure 5b).
This suggests that DI inhibits the pathogenic effect of APS-
positive IgG through a decoy mechanism, in which it binds the
APS during the pre-incubation stage, therefore causing a
protective effect. Additionally, the serum from the APS-positive
IgG samples selected were tested in a competition based
ELISA, to see if fluid-phase recombinant DI could inhibit IgG
from binding to solid-phase β2GPI. It was observed that
increasing DI concentrations reduced binding (Figure 5c),
which correlated with reductions in cleaved caspase-3
(Figure 5d), further supporting the case that it is anti-DI
antibodies that are the dominant pathogenic population in this
in vitro H/R cardiac injury simulation model. However, to
definitively prove that anti-DI are the pathogenic
Figure 2 IgG from patients with SLE/APS +ve, SLE/APS –ve and APS enhances
cleaved caspase-3 in neonatal rat cardiomyocytes in H/R injury. Cells were pre-
treated with 500 μg/ml healthy, SLE/APS negative, SLE/APS positive or primary APS
IgG. The following day cells were exposed to H/R injury (4 h hypoxia+4 h
reoxygenation) and the level of cleaved caspase-3 was assessed by western blot.
Graph shows ±S.E.M. of quantitative analysis from five SLE/APS-positive patients,
five SLE/APS-negative patients, six primary APS patients and ten healthy controls.
Graphical representations of the density ratios of each protein and GAPDH
expressed as a percentage of untreated cells are displayed. Statistical analysis
determined by one-way ANOVA using post hoc tukey to compare all columns
(***Po0.0005)
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subpopulation of aPL that enhance cardiomyocyte H/R injury,
these antibodiesmust be affinity purified frommultiple patients
and then tested in an in vivo cardiac H/R model, ideally
comparedwith affinity purified anti-β2GPI antibodies binding to
domains other than DI. The results presented in this article
underpin these detailed future in vivo studies.
The next question to be answered is what cell surface
receptors β2GPI is binding to, to induce this response. It has
previously been shown that β2GPI has the ability to bind
to a range of receptors including TLR4, TLR2, Annexin A2 and
Ro 60.33–36 A known downstream activator of TLR4 is p38
MAPK22 and therefore it could be suggested that the APS
autoantibodies are mediating their pathogenic effect via this
receptor. Additionally, TLR4 has been implicated in I/R injury,
with TLR4-deficient mice showing cardioprotection in an in vivo
I/R injury model.37,38 Further experiments are now required to
confirm this.
In humans, there is no large-scale study to our knowledge
that has compared cardiac infarct sizes between patients with
APS±SLE and age- and gender-matched controls. This
in vitro study provides the first evidence that autoantibodies, a
prominent feature of patients with APS±SLE, may play a role
in the degree of damage to the myocardium in I/R injury and
propose a novel non-thrombotic role for these autoantibodies
Figure 3 IgG purified from APS patients increases the pro-apoptotic kinase p38 MAPK phosphorylation in neonatal rat cardiomyocytes in H/R injury. Cells were pre-treated
with 500 μg/ml IgG (APS (primary or SLE/APS) and SLE/APS negative). The following day cells were exposed to H/R injury (4 h hypoxia+4 h reoxygenation) and the levels of p38
MAPK (a), Akt (b) and ERK 1/2 (p42/p44) (c) phosphorylation assessed using western blot. Graphical representations of the density ratios of each phosphorylated to total protein
expressed in arbitrary scanning units are displayed. Graph shows± S.E.M. of quantitative analysis from five independent experiments. Statistical analysis determined by
unpaired t-test (*P= 0.0179)
Antiphospholipid antibodies enhance cardiac H/R injury
LT Bourke et al
5
Cell Death and Disease
in this organ. Further studies using affinity purified anti-DI
antibodies within a passive transfer animal model of cardiac
I/R injury to confirm pathogenicity in vivo are now required.
The outcome of this research may identify a new mechanism
through which antibodies from patients with APS±SLE may
cause cardiac damage following an MI. This research could
then underpin future clinical studies to determine if patients
with APS±SLE are susceptible to a larger MI and/or stroke as
compared with age- and gender-matched controls. Ultimately,
this may lead to identification of novel pathogenic roles for
antibodies from patients with APS±SLE and investigation of
potential new targets and therapeutics with the aim of
ultimately improving outcomes for patients with these condi-
tions and cardiovascular disease.
Materials and Methods
Patients. Serum samples were obtained from 35 individuals for this study with
informed consent and local ethical approval in accordance with the Declaration of
Helsinki. We studied three groups of subjects. The first group of 11 patients had
APS; 5 with SLE-associated APS (1 vascular thrombosis (VT) and pregnancy
morbidity (PM) and 4 VT) and 6 with primary APS (1 PM and 5 VT). The second
group of nine patients had SLE but no serum aPL and no clinical features of APS.
The third group were 15 healthy controls (HCs) who also had no serum aPL. All
patients with APS and SLE fulfilled the current accepted classification criteria.39,40
Immunological characterisation and purification of IgG. IgG was
protein G purified, passed through endotoxin removal columns (Pierce, Thermo-
Fisher, Basingstoke, UK), and confirmed to be o0.06 endotoxin units per millilitre
by Limulus ameboycte lysate assay (Sigma-Aldrich, St. Louis, MO, USA) as
described previously.41 Total IgG concentration was determined by spectro-
photometry. Serum and IgG aCL, anti-β2GPI and anti-DI titres were determined by
enzyme-linked immunosorbent assay (ELISA) as described previously.31 Serum
levels are reported in Table 1, activity levels were re-confirmed after IgG purification
and activity was retained (data not shown).
Expression and purification of recombinant DI. Expression of wild-
type recombinant human DI in Escherichia coli and purification using cytoplasmic
inclusion bodies from which DI can be re-folded was performed as described
previously.42 Subsequent cleavage with factor Xa removed the hexahistidine tag,
resulting in native DI peptide.
Competitive inhibition assay. A competitive inhibition ELISA was used to
assess the ability of recombinant DI in the fluid phase to inhibit binding of aPL to
solid phase whole β2GPI. Prior to the assay, our in-house standard β2GPI ELISA
previously described32 was used to assess at what dilution of serum corresponded
to 50% of the maximal binding absorbance unit of the serum. This ELISA was then
repeated with the following amendment – anti-β2GPI inhibition curves were
constructed by pre-incubating sera from patients with APS with varying
concentrations of recombinant DI (ranging from 0 to 80 μg/ml) for 2 h at room
temperature prior to addition to a 96-well plate.
Primary neonatal rat ventricular cardiomyocyte isolation. Primary
cardiomyocytes were isolated as previously described.43 All animal studies were
approved by the University College London Biological Services Ethical Review
Committee and licensed under the UK Home Office regulations and the Guidance
for the Operation of Animals (Scientific Procedures) Act 1986 (Home Office,
London, UK). All isolation buffers were oxygenated by bubbling medical grade
oxygen through the solution for 5 min prior to use. Neonate rat pups (Sprague-
Dawley) that wereo2day postpartum were decapitated and rinsed in ethanol. The
hearts were removed by cutting along the sternum and dissecting the heart through
the chest wall. Hearts were washed in isolation buffer (116 mM NaCl, 20 mM
HEPES, 0.77 mM NaH2PO, 5.5 mM glucose, 5.4 mM KCl, 0.4 mM MgSO
containing 600 μg/ml collagenase type II and 250 μg/ml pancreatin) and cut into
small 2 mm pieces and then incubated at 37 °C until plating. The digestion
procedure was repeated seven times and the pellets pooled and pre-plated for 1 h
in 15% (v/v) fetal bovine serum (FBS) in DMEM to remove contaminating
fibroblasts. Cardiomyocytes were then seeded at 2 ×106 cells per well of a six-well
plate, which had been pre-coated with 1% (w/v) gelatin (Sigma-Aldrich). The DMEM
containing 15% (v/v) FBS was replaced the following day with maintenance media
(DMEM containing 1% (v/v) FBS) or 1% Human Apo H Deficient Serum (Assay
Pro). For IgG incubations cells were pre-treated with 500 μg/ml purified polyclonal
IgG from patient or healthy control serum overnight prior to H/R injury. For DI
peptide experiments, IgG was pre-incubated with 40 μg recombinant DI peptide for
2 h at room temperature, prior to incubation with cells. A control experiment was
performed, whereby cells were incubated with bovine serum albumin (BSA) at
500 μg/ml to confirm that the effect observed was IgG specific. No difference in
cleaved caspase-3 was observed when compared with untreated cells (data not
shown).
In vitro H/R injury. Cell culture media was replaced with ischaemic buffer
(137 mM NaCl, 12 mM KCl, 0.49 mM MgCl, 0.9 mM CaCl2
. H20, 4 mM HEPES,
20 mM sodium lactate and 10 mM deoxyglucose (pH 6.2)) and cells transferred to
an in-house built anoxic chamber pre-warmed to 37 °C. Simulated ischaemia
was achieved by addition of 5% CO2 in balanced argon to exclude any oxygen.
Figure 4 The p38 inhibitor SB23580 prevents IgG from APS patients enhancing cleaved caspase-3 in neonatal rat cardiomyocytes in H/R injury. Cells were pre-treated with
10 μM SB203580 and 2 h later 500 μg/ml IgG (healthy, APS positive (primary and SLE/APS) and SLE/APS negative). The following day cells were exposed to H/R injury (4 h
hypoxia+2 h reoxygenation) and the levels of cleaved caspase-3 and phosphorylated MAP kinase-activated protein kinase 2 (p-MAPKAPK2) were assessed using western blot.
Graph shows ± S.E.M. of quantitative analysis from four independent experiments. Graphical representations of the density ratios of each protein and GAPDH expressed in
arbitrary scanning units are displayed. Statistical analysis determined by unpaired t-test (*P= 0.0256, *P= 0.0286)
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Cells were subjected to simulated ischaemic injury for 4 h after which ischaemic
buffer was replaced with DMEM containing 1% (v/v) FBS and cultured in 5% CO2 in
air (simulated reperfusion) for the indicated times. Optimisation of H/R injury was
performed using TUNEL (Supplementary Figure S1).
Determination of apoptosis. Cells were seeded on UV-irradiated coverslips
and fixed in 4% (w/v) paraformaldehyde in phosphate-buffered saline (PBS) for
15 min at room temperature. In situ cell death was detected in cultured
cardiomyocytes by using TUNEL assay kit (Roche Diagnostics, Meylan, France)
according to the manufacturer’s instructions. Cells were then washed and cell nuclei
counter stained with DAPI. Coverslips were mounted onto glass slides using a Zeiss
Axioscope inverted fluorescence microscope (Zeiss, Oberkochen, Germany).
Western blotting. Cells were lysed in 1 × RIPA buffer (20 mM TRIS-HCl (pH
7.5), 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% (v/v) IGEPAL, 1% (w/v)
deoxycholate, 250 mM sodium pyrophosphate and Complete-mini protease inhibitor
cocktail (Roche, Basel, Switzerland) and incubated on ice for 15 min. Lysates were
spun at 13 000 r.p.m. for 5 min to pellet cell debris. The supernatant was transferred
to a clean tube and assayed for protein using the BCA assay kit according to the
manufacturer’s instructions (Pierce). Twenty micrograms total protein was run on
denaturing PAGE gels in protein running buffer (25 mM TRIS-HCl, 192 mM glycine,
0.1% (w/v) sodium dodecyl sulphate) and wet-transferred in transfer buffer (25 mM
TRIS-HCl, 192 mM glycine, 0.1% (w/v) sodium dodecyl sulphate containing 20%
(v/v) methanol) to Hybond-C nitrocellulose membrane (GE Healthcare, Little
Chalfont, UK). Membranes were blocked for 60 min in 5% (w/v) non-fat dry milk in
PBS for 1 h at room temperature before being incubated with primary antibody
Figure 5 The pathogenic effect of APS-positive IgG is reduced in the presence of fluid-phase DI peptide. Neonatal rat cardiomyocytes were cultured in human β2GPI-
deficient serum (+/− spiked human β2GPI at a final concentration of 200 μg/ml) and pre-treated overnight with 500 μg/ml IgG (pooled from 5 patients per group) (a). IgG purified
from APS positive (primary APS or SLE/APS) (n = 9) SLE/APS negative (n = 7) or healthy controls (n = 8) were pre-incubated for 2 h at room temperature with 40 μg of
recombinant DI peptide or PBS. Cells were then treated with IgG+PBS/IgG+DI overnight (b). The following day cells were exposed to H/R injury (4 h hypoxia+2 h reoxygenation)
and levels of cleaved caspase-3 were assessed using western blot (a+b). A competition based ELISA was performed to measure the ability of DI to bind to IgG from the APS-
positive group (n= 9) (c). The percentage aPL-β2GPI binding at 40 μg of DI peptide correlated with percentage reduction in cleaved caspase-3 for the APS positive (primary APS
and SLE/APS positive) samples (r= 0.6755, P= 0.0459) (n = 9) (d). Graphical representations of the density ratios of each protein and GAPDH expressed as a percentage of
increase of IgG+DI compared with IgG+PBS are displayed. Statistical analysis determined by Mann–Whitney U-test (a) (*P= 0.0145, **P= 0.0045)
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(Cell Signalling Danvers, MA, USA) overnight at 1/1000 dilution in 5% (w/v) non-fat
dry milk in PBS at 4 °C. The following day they were washed three times in PBS
containing 0.1% (v/v) Tween-20. Horseradish-peroxidase conjugated secondary
antibodies (DAKO, Ely, UK) were used at 1/5000 dilution in 5% (w/v) non-fat dry milk
for 1 h at room temperature and then washed three times in PBS containing 0.1%
(v/v) Tween-20. Bands were visualised using enhanced chemiluminescence
(GE Healthcare, UK).
Statistical analysis. Statistical analyses were performed using GraphPad
Prism software 4.0c (GraphPad Software, La Jolla, CA, USA). Normally distributed
data were analysed by parametric t-test and non-normally distributed data by non-
parametric Mann–Whitney U-test. For multiple means comparisons, one-way
analysis of variance (ANOVA) followed by Tukey post hoc test was used to
determine statistical significance.
Study approval. All animal studies were approved by the University College
London Biological Services Ethical Review Committee and licensed under the UK
Home Office regulations and the Guidance for the Operation of Animals (Scientific
Procedures) Act 1986 (Home Office, London, UK).
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